Neuroderm Ltd. shares (NASDAQ: NDRM) climbed 26.6 percent Wednesday to $29.30 on word that a 24-hour regimen of its continuous delivery levodopa/carbidopa (LD/CD) candidate, ND0612H, significantly decreased the amount of time in which Parkinson's disease (PD) patients faced a reemergence of PD symptoms on medication, eliminating it altogether for some patients.